Related Experiment Video
Updated: Apr 4, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
14.5K
New oral anticoagulants - a practical guide
Tomasz Ciurus1, Sebastian Sobczak1, Anna Cichocka-Radwan1
1Department of Cardiology, Chair of Cardiology and Cardiac Surgery, Medical University of Lodz, Poland.
Summary
New oral anticoagulants offer predictable effects without routine monitoring but lack antidotes. Management of bleeding involves supportive care, factor administration, and specialized tests, with specific antidotes in development.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- New oral anticoagulants (NOACs) targeting thrombin and Factor Xa are approved.
- Unlike traditional anticoagulants (VKAs, heparins), NOACs have predictable pharmacokinetics and single targets.
- NOACs do not require routine coagulation monitoring but may benefit from pharmacologic effect measurement in select cases.
Purpose of the Study:
- To provide simplified answers to clinical questions regarding new oral anticoagulants.
- To review the management of bleeding complications associated with NOACs.
- To discuss the role of specific coagulation tests and antidotes for NOACs.
Main Methods:
- Literature review of clinical studies and guidelines on NOACs.
- Analysis of pharmacokinetic and pharmacodynamic properties of NOACs.
- Synthesis of information on managing bleeding and emergency situations involving NOACs.
Main Results:
- NOACs interfere with standard coagulation tests, requiring cautious interpretation.
- Specific assays are available for measuring NOAC effects, particularly in emergencies.
- Supportive care, removal of antithrombotics, and coagulation factor administration are key in bleeding management.
- Specific antidotes for NOACs are under clinical development.
Conclusions:
- While NOACs offer advantages, their lack of readily available antidotes presents a challenge.
- Careful interpretation of coagulation tests and availability of specific assays are crucial.
- Management strategies for bleeding complications are evolving with the development of targeted antidotes.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:29Venous Thrombosis III: Interprofessional Care
466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:30Venous Thrombosis IV: Nursing Management
387
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
387
01:27Coronary Artery Disease V: Interprofessional Care
418
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418